GARDskin approved by OECD

THE FIRST AND ONLY Genomics and Machine-learning based in vitro skin sensitization assay

Get a quote

Sensitization Testing with GARD®

Regulatory Toxicity Testing

Biological Evaluation of Medical Devices

The GARD® technology: An holistic approach

Learn more about the improved accuracy and human relevance

SenzaGen provides state-of-the-art non-animal tests for assessing a substance’s allergenicity. With excellent predictivity, the tests meet needs in several industries and help companies develop, produce and deliver safer, ethical and more sustainable products.

GLP Compliant Laboratory

READ MORE

Meet SenzaGen.

SenzaGen webinars

Webinar: In vitro skin sensitization potency assessment – Part 1

May 6 @ 16:00 - 17:00

2026 AFI Symposium

June 10 @ 08:00 - June 12 @ 17:00Rimini
EVENT CALENDAR

Press Releases

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
13 Feb, 2026
News
IR
English
Regulatory
MAR
Corporate Information
Other Corporate Information
mfn-ext-nq
mfn-ext-nq-inside-information
SenzaGen carries out a directed issue of approximately SEK 17.5 million to the institutional investor Eiffel Investment Group
13 Feb, 2026
News
IR
English
Regulatory
MAR
Report
Interim
Yearend
SenzaGen’s Year-End Report 2025 | SenzaGen closes the year with continued strong GARD® sales
06 Feb, 2026
News
IR
English
Corporate Information
Other Corporate Information
mfn-ext-nq
mfn-ext-nq-company-announcement
Invitation to the presentation of SenzaGen's year-end report 2025
PreviousNext

News Posts

Subscribe


Prenumerera